Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.
Park B, Dennis F, He AZ, Krishnaraj A, Bakbak E, Dennis CJ, Pan Y, Misner E, Thayanithy V, Lambotharan B, Lambotharan V, Lambotharan A, Mazer CD, Quan A, Teoh H, Hess DA, Verma S. Park B, et al. Among authors: bakbak e. Eur Heart J. 2026 Mar 9;47(10):1171-1182. doi: 10.1093/eurheartj/ehaf690. Eur Heart J. 2026. PMID: 40886061 Free PMC article. Clinical Trial.
Vascular Regenerative Cell Deficiencies in South Asian Adults.
Krishnaraj A, Bakbak E, Teoh H, Pan Y, Firoz IN, Pandey AK, Terenzi DC, Verma R, Bari B, Bakbak AI, Kunjummar SP, Yanagawa B, Connelly KA, Mazer CD, Rotstein OD, Quan A, Bhatt DL, McGuire DK, Hess DA, Verma S. Krishnaraj A, et al. Among authors: bakbak e. J Am Coll Cardiol. 2024 Feb 20;83(7):755-769. doi: 10.1016/j.jacc.2023.12.012. J Am Coll Cardiol. 2024. PMID: 38355246 Free article.
Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial.
Barbour W, Wolff E, Puar P, Hibino M, Bakbak E, Krishnaraj A, Verma R, Verma M, Quan A, Yan AT, Connelly KA, Teoh H, Mazer CD, Verma S. Barbour W, et al. Among authors: bakbak e. BMC Cardiovasc Disord. 2023 Nov 15;23(1):557. doi: 10.1186/s12872-023-03549-5. BMC Cardiovasc Disord. 2023. PMID: 37964221 Free PMC article. Clinical Trial.
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling.
Bakbak E, Verma S, Krishnaraj A, Quan A, Wang CH, Pan Y, Puar P, Mason T, Verma R, Terenzi DC, Rotstein OD, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. Bakbak E, et al. Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1210-H1222. doi: 10.1152/ajpheart.00141.2023. Epub 2023 Sep 29. Am J Physiol Heart Circ Physiol. 2023. PMID: 37773589 Free article. Clinical Trial.
Vascular regenerative cells in cardiometabolic disease.
Bakbak E, Krishnaraj A, Park B, Verma S, Hess DA. Bakbak E, et al. Curr Opin Cardiol. 2023 Nov 1;38(6):546-551. doi: 10.1097/HCO.0000000000001089. Epub 2023 Aug 30. Curr Opin Cardiol. 2023. PMID: 37668181
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease.
Krishnaraj A, Bakbak E, Teoh H, Bhatt DL, Quan A, Puar P, Lambotharan B, Kirubaharan A, Firoz IN, Meglis G, Yanagawa B, Bari B, Kirubaharan R, Vijayaraghavan R, Hess DA, Demchuk AM, Mancini GBJ, Tanguay JF, Tardif JC, Voisine P, Leiter LA, Verma S. Krishnaraj A, et al. Among authors: bakbak e. Med. 2023 Feb 10;4(2):130-138.e1. doi: 10.1016/j.medj.2022.12.008. Epub 2023 Jan 10. Med. 2023. PMID: 36630964 Free article.
14 results